Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 10

Articles by Marisa Woutersen

Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
Regulation & Industry
Perfect Pitch: Inside the scheme that gets junior lawyers selling to clients
Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms.   14 September 2026
Built to be bought? What makes companies acquisition-ready
Regulation & Industry
Built to be bought? What makes companies acquisition-ready
For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.   11 September 2026
J&J names two-decade veteran as chief IP counsel
Careers
J&J names two-decade veteran as chief IP counsel
The senior lawyer previously led Johnson & Johnson’s global pharmaceutical patent team, advising on patent portfolios, R&D, licensing, M&A and litigation.   10 September 2026
Pharma
J&J unit win shuts door on Sandoz generic launch
Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market.   10 September 2026
MedTech
Abbott clinches 18-country PI in glucose monitoring feud
The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent.   9 September 2026
Pharma
Italy’s Biofer falls short in Fed Circ appeal over key claim wording
A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies.   7 September 2026
Regulation & Industry
G 1/25: EPO settles controversial patent description question
Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling.   4 September 2026
MedTech
Sun Pharma import ban back in force after Squires intervention
A decision at the USPTO has cleared the way for renewed enforcement in the drugmaker’s dispute over light-based dermatology tech.   3 September 2026
Careers
‘Busiest’ US district patent judge swaps bench for private practice
One of the country's most prominent patent judges has joined A&O Shearman after nearly eight years on the federal bench.   2 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
While promising science draws in buyers, intellectual property determines the price, terms, and viability of an agreement. LSIPR digs into what investors are looking for—and the biggest turn-offs that destroy a deal.   25 August 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.